九安醫療(002432.SZ)：前三季度淨利預降86.23%-90.36%
格隆匯10月14日丨九安醫療(002432.SZ)公佈2021年前三季度業績預吿，公司歸屬於上市公司股東的淨利潤3500萬元至5000萬元，比上年同期下降86.23%-90.36%；基本每股收益0.0770元至0.1099元。
2021年第三季度歸屬於上市公司股東的淨利潤為-1978萬元至-478萬元，基本每股收益為虧損-0.0435元至-0.0105元。
公司2021年前三季度業績較去年同期下降，主要原因如下：
一、受2020年疫情影響，國內外市場測温產品和其他防疫物資需求激增，一度處於供不應求的狀態。公司快速響應國家衞生防疫需求，提前恢復生產，積極擴大產能，並在國內疫情緩解後，於2020年3月中旬開始去年向國外出口額温計等防疫產品，因此，去年同期公司業績大幅增長。報吿期，國內外疫情趨於好轉，加之全球防疫產品產能的持續供給，防疫物資的緊缺情況有所緩解且防疫產品毛利率下滑。
二、公司的糖尿病診療照護“O+O”新模式已經進入了快速發展通道，公司計劃未來4年在國內47個城市建立約600個照護門診中心，管理約100萬名患者。報吿期內國內照護中心數量大幅增加，合作醫院數量較2020年末增加了近1.5倍。隨着糖尿病診療照護“O+O”新模式項目規模的加速擴張，設備、人員等投入的增加，導致相關支出增長。我國近幾年陸續出台了對互聯網+醫療領域的支持政策，互聯網+醫療服務納入醫保報銷範圍工作正在逐步推進，美國醫保也已經明確了付費方式，公司的糖尿病診療照護“O+O”新模式迎來了良好的發展機遇，公司會持續加大在互聯網+醫療業務的投入，加速推動糖尿病診療照護“O+O”新模式項目在國內外的落地和普及。
隨着糖尿病診療照護“O+O”新模式這一核心戰略的推進，血糖類產品銷量將會隨之提升。此外，公司在保持血壓計、血糖儀等主要產品銷量穩定的同時，將堅持貫徹“在新零售平台推出極致性價比爆款產品”的核心戰略。目前已經相繼上線瞭如額温計、智能手錶、體脂秤、耳温計等多款產品，公司將繼續在中國、美國的新零售平台推出更多受到市場和消費者認可的爆款產品，為公司貢獻收入和利潤，努力提升業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
